{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:47:56Z","timestamp":1778633276740,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013813","name":"AMGC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013813","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jacl.2022.05.002","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T04:31:46Z","timestamp":1652243506000},"page":"498-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Attainment of low-density lipoprotein cholesterol goals in patients treated with combination therapy: A retrospective cohort study in primary care"],"prefix":"10.1016","volume":"16","author":[{"given":"Clara","family":"Marquina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Talic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9993-4297","authenticated-orcid":false,"given":"Ella","family":"Zomer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4019-2089","authenticated-orcid":false,"given":"Sandra","family":"Vargas-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjana","family":"Petrova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2126-1045","authenticated-orcid":false,"given":"Rory","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Abushanab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8293-7910","authenticated-orcid":false,"given":"Sean","family":"Lybrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2329-6903","authenticated-orcid":false,"given":"Giles","family":"Stratton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Ofori-Asenso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Liew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2582-0374","authenticated-orcid":false,"given":"Zanfina","family":"Ademi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10226","key":"10.1016\/j.jacl.2022.05.002_bib0001","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(19)32008-2","article-title":"Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study","volume":"395","author":"Yusuf","year":"2020","journal-title":"Lancet North Am Ed"},{"issue":"10159","key":"10.1016\/j.jacl.2022.05.002_bib0002","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Roth","year":"2018","journal-title":"Lancet North Am Ed"},{"issue":"10","key":"10.1016\/j.jacl.2022.05.002_bib0003","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","article-title":"Impact of lipids on cardiovascular health: JACC health promotion series","volume":"72","author":"Ference","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2022.05.002_bib0004","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/cpt.1125","article-title":"LDL-cholesterol is the only clinically relevant biomarker for atherosclerotic cardiovascular disease (ASCVD) risk","volume":"104","author":"Ofori-Asenso","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"32","key":"10.1016\/j.jacl.2022.05.002_bib0005","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"34","key":"10.1016\/j.jacl.2022.05.002_bib0006","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacl.2022.05.002_bib0007","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2022.05.002_bib0008","unstructured":"National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. 2012."},{"issue":"10170","key":"10.1016\/j.jacl.2022.05.002_bib0009","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","author":"Armitage","year":"2019","journal-title":"Lancet North Am Ed"},{"issue":"19","key":"10.1016\/j.jacl.2022.05.002_bib0010","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.2015.15629","article-title":"Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force","volume":"316","author":"Chou","year":"2016","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.jacl.2022.05.002_bib0011","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/heartjnl-2018-314253","article-title":"Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease","volume":"105","author":"Akyea","year":"2019","journal-title":"Heart"},{"issue":"2122","key":"10.1016\/j.jacl.2022.05.002_bib0012","article-title":"Statin treatment and LDL target value achievement in Swiss general practice \u2013 a retrospective observational study","volume":"150","author":"Rachamin","year":"2020","journal-title":"Swiss Med Wkly [Internet]"},{"key":"10.1016\/j.jacl.2022.05.002_bib0013","article-title":"Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada","author":"Gitt","year":"2011","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"10.1016\/j.jacl.2022.05.002_bib0014","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1161\/STROKEAHA.119.028718","article-title":"Benefit of targeting a LDL (Low-Density Lipoprotein) cholesterol <70 mg\/dL during 5 years after ischemic stroke","volume":"51","author":"Pierre","year":"2020","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.jacl.2022.05.002_bib0015","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1161\/ATVBAHA.109.188474","article-title":"Identification of genetic variants associated with response to statin therapy","volume":"29","author":"Mega Jessica","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2022.05.002_bib0016","unstructured":"Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of Nonadherence to Statins: A Systematic Review and Meta-Analysis: Ann Pharmacother [Internet]. 2010 Aug 11 [cited 2020 Nov 30]; Available from: https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1P150"},{"issue":"8","key":"10.1016\/j.jacl.2022.05.002_bib0017","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11886-020-01326-w","article-title":"Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets","volume":"22","author":"Masana","year":"2020","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"10.1016\/j.jacl.2022.05.002_bib0018","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.acvd.2016.11.004","article-title":"Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS\/CHD study","volume":"110","author":"Ferri\u00e8res","year":"2017","journal-title":"Arch Cardiovasc Dis"},{"issue":"25","key":"10.1016\/j.jacl.2022.05.002_bib0019","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jacl.2022.05.002_bib0020","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.05.002_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00547","article-title":"Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis","author":"Chaiyasothi","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacl.2022.05.002_bib0022","unstructured":"Office of the Australian Information Commissioner. The Australian Privacy Principles. From Schedule 1 of the Privacy Amendment (Enhancing Privacy Protection) Act 2012. 2014 Jan;19."},{"key":"10.1016\/j.jacl.2022.05.002_bib0023","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","article-title":"Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries","volume":"285","year":"2019","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.jacl.2022.05.002_bib0024","article-title":"Adherence to lipid-lowering guidelines for secondary prevention and potential reduction in CVD events in Swedish primary care: a cross-sectional study","volume":"10","author":"\u00d6desj\u00f6","year":"2020","journal-title":"BMJ Open [Internet]."},{"issue":"4","key":"10.1016\/j.jacl.2022.05.002_bib0025","doi-asserted-by":"crossref","first-page":"e13861","DOI":"10.1111\/ijcp.13861","article-title":"Does management of lipid lowering differ between specialists and primary care: Insights from GOAL Canada","volume":"75","author":"Langer","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jacl.2022.05.002_bib0026","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.atherosclerosis.2016.07.001","article-title":"Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan","volume":"251","author":"Teramoto","year":"2016","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.jacl.2022.05.002_bib0027","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00228-018-2518-1","article-title":"Demographic, clinical and lifestyle factors associated with high-intensity statin therapy in Australia: the AusDiab study","volume":"74","author":"Ho","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.jacl.2022.05.002_bib0028","first-page":"1270","article-title":"Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia","volume":"23","author":"Menzin","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jacl.2022.05.002_bib0029","article-title":"EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study","author":"Ray","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2022.05.002_bib0030","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jacl.2020.11.004","article-title":"PCSK9 inhibition in clinical practice: Treatment patterns and attainment of lipid goals in a large health maintenance organization","volume":"15","author":"Zafrir","year":"2021","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2022.05.002_bib0031","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bcp.12339","article-title":"Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review","volume":"78","author":"De Vera","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jacl.2022.05.002_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201196","article-title":"Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease","volume":"14","author":"Hope","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jacl.2022.05.002_bib0033","article-title":"Trends in the utilisation of lipid-lowering medications in Australia: an analysis of national pharmacy claims data","author":"Talica","year":"2021","journal-title":"Curr Probl Cardiol"},{"issue":"4","key":"10.1016\/j.jacl.2022.05.002_bib0034","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004371.pub2","article-title":"Interventions to improve adherence to lipid lowering medication","author":"Schedlbauer","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacl.2022.05.002_bib0035","unstructured":"Australia, Productivity Commission. Efficiency in health. 2015."},{"key":"10.1016\/j.jacl.2022.05.002_bib0036","article-title":"What Is Pay for Performance in Healthcare?","author":"Catalyst","year":"2018","journal-title":"NEJM Catal"},{"key":"10.1016\/j.jacl.2022.05.002_bib0037","article-title":"Current perceptions and practices in lipid management: results of a European Society of Cardiology\/European Atherosclerosis Society Survey","author":"Koskinas","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2022.05.002_bib0038","article-title":"Examination of physicians\u2019 adherence to the 2013 ACC\/AHA statin\/cholesterol guidelines using a framework of awareness to adherence: A cross-sectional study","volume":"9","author":"Fleming","year":"2020","journal-title":"JRSM Cardiovasc Dis"},{"issue":"100","key":"10.1016\/j.jacl.2022.05.002_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta191000","article-title":"Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling","volume":"19","author":"Perera","year":"2015","journal-title":"Health Technol Assess Winch Engl"},{"key":"10.1016\/j.jacl.2022.05.002_bib0040","article-title":"Gender gap in risk factor control of coronary patients far from closing: results from the European Society of Cardiology EUROASPIRE V registry","author":"Vynckier","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2022.05.002_bib0041","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jacc.2011.09.067","article-title":"Meta-Analysis of Statin Effects in Women Versus Men","volume":"59","author":"Kostis William","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jacl.2022.05.002_bib0042","article-title":"Sex Differences in the Use of Statins in Community Practice","volume":"12","author":"G","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacl.2022.05.002_bib0043","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/957105","article-title":"Age- and Gender-Related Differences in LDL-Cholesterol Management in Outpatients with Type 2 Diabetes Mellitus","author":"Russo","year":"2015","journal-title":"Int J Endocrinol"},{"issue":"4","key":"10.1016\/j.jacl.2022.05.002_bib0044","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2016.02.016","article-title":"Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study","volume":"10","author":"Karalis","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.jacl.2022.05.002_bib0045","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.pcad.2020.03.012","article-title":"Non-statin interventions in the prevention of cardiovascular events: Sex-based meta-analysis","volume":"63","author":"Das","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"issue":"3","key":"10.1016\/j.jacl.2022.05.002_bib0046","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1037\/hea0000122","article-title":"How do general practitioners and patients make decisions about cardiovascular disease risk?","volume":"34","author":"Bonner","year":"2015","journal-title":"Health Psychol"},{"issue":"2","key":"10.1016\/j.jacl.2022.05.002_bib0047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191817","article-title":"Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk","volume":"13","author":"Fung","year":"2018","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.jacl.2022.05.002_bib0048","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1016\/j.jacc.2018.08.2191","article-title":"Switching, Discontinuation, and Reinitiation of Statins Among Older Adults","volume":"72","author":"Ofori-Asenso","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2022.05.002_bib0049","article-title":"General Practice: Health of the Nation 2020 [Internet]","year":"2020","journal-title":"RACGP"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287422000800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287422000800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:37:49Z","timestamp":1761831469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287422000800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1933287422000800"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2022.05.002","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Attainment of low-density lipoprotein cholesterol goals in patients treated with combination therapy: A retrospective cohort study in primary care","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2022.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 National Lipid Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}